MultiCell Technologies, Inc.

Liver-cell based technologies and products for the development of new medicines and treatments for liver-related diseases

The company was founded (as Multicell Associates Inc.) in 1995 by the late Hugo Jauregui, Alfred Vasconcellos, Pierre Galletti and Jayanta Roy Chowdhury. In 2001, the company was acquired by Exten Industries, Inc. MultiCell is a public Rhode Island-based cell technology company which trades on the OTC Electronic Bulletin Board under the symbol MCET.OB.

MultiCell’s majority-owned subsidiary, Xenogenics Corporation, is developing the Sybiol® biosynthetic liver device that utilises MultiCell’s proprietary, immortalised human hepatocytes.

68 Cumberland Street, Suite 301
Woonsocket, RI 02895
USA
Phone: +1-401-762-0045
Fax: +1-762-0098

MultiCell is a leading provider of immortalised human liver cells. The technologies are applied in drug discovery research, therapeutic protein production, liver stem cells, and artificial liver support. Multicell specialises in innovative cell immortalisation technologies for creating highly functional, continually reproducible, human liver cell lines.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.